Initial activation status of the antioxidant response determines sensitivity to carboplatin/paclitaxel treatment of ovarian cancer

Anticancer Research

Volumn 32, Issue 11, 2012, Pages 4723-4728

  Pons, Daniel G ^a   Sastre Serra, Jorge ^a   Nadal Serrano, Mercedes ^a   Oliver, Aina ^a,b   García Bonafé, Magdalena ^a,b   Bover, Isabel ^a,b   Roca, Pilar ^a   Oliver, Jordi ^a  

^a UNIVERSITAT DE LES ILLES BALEARS   (Spain)

^b HOSPITAL SON LLÀTZER   (Spain)

Author keywords

Antioxidant response; Carboplatin; Chemotherapy resistance; Ovarian cancer; Paclitaxel

Indexed keywords

ANTIOXIDANT; CARBOPLATIN; CATALASE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; PACLITAXEL; UNCOUPLING PROTEIN;

ADULT; ARTICLE; CANCER PATIENT; CANCER RESISTANCE; CANCER TISSUE; CHEMOSENSITIVITY; CONTROLLED STUDY; CYSTADENOCARCINOMA; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIOXIDANTS; BLOTTING, WESTERN; CARBOPLATIN; CYSTADENOCARCINOMA, SEROUS; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ION CHANNELS; MITOCHONDRIAL PROTEINS; OVARIAN NEOPLASMS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PACLITAXEL;

EID: 84872660685     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Cannistra SA: Cancer of the ovary. N Engl J Med 351: 2519-2529, 2004.
2. Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7: 573-584, 2007.
3. Honore S, Pasquier E and Braguer D: Understanding microtubule dynamics for improved cancer therapy. Cell Mol Life Sci 62: 3039-3056, 2005.
4. Alexandre J, Hu Y, Lu W, Pelicano H and Huang P: Novel action of paclitaxel against cancer cells: Bystander effect mediated by reactive oxygen species. Cancer Res 67: 3512-3517, 2007.
5. Cheng CF, Juan SH, Chen JJ, Chao YC, Chen HH, Lian WS, Lu CY, Chang CI, Chiu TH and Lin H: Pravastatin attenuates carboplatin-induced cardiotoxicity via inhibition of oxidative stress associated apoptosis. Apoptosis 13: 883-894, 2008.
6. Goto T, Takano M, Hirata J and Tsuda H: The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers. Br J Cancer 98: 1068-1075, 2008.
7. Husain K, Whitworth C, Hazelrigg S and Rybak L: Carboplatin-induced oxidative injury in rat inferior colliculus. Int J Toxicol 22: 335-342, 2003.
8. Panis C, Herrera AC, Victorino VJ, Campos FC, Freitas LF, De Rossi T, Colado Simao AN, Cecchini AL and Cecchini R: Oxidative stress and hematological profiles of advanced breast cancer patients subjected to paclitaxel or doxorubicin chemotherapy. Breast Cancer Res Treat 133: 89-97, 2012.
9. Roca P, Oliver J, Sastre-Serra J, and Nadal-Serrano M: The Importance of ERalfa/ERbeta Ratio in Breast Cancer: Mitochondrial Function and Oxidative Stress. In: Breast Cancer. Carcinogenesis, Cell Growth and Signalling Pathways. Gunduz M, Gunduz E eds. Rijeka: InTech, p. 732, 2011.
10. Roy D, Cai Q, Felty Q and Narayan S: Estrogen-induced generation of reactive oxygen and nitrogen species, gene damage, and estrogen-dependent cancers. J Toxicol Environ Health B Crit Rev 10: 235-257, 2007.
11. Clinton GM and Hua W: Estrogen action in human ovarian cancer. Crit Rev Oncol Hematol 25: 1-9, 1997.
12. Laurent A, Nicco C, Chereau C, Goulvestre C, Alexandre J, Alves A, Levy E, Goldwasser F, Panis Y, Soubrane O, Weill B and Batteux F: Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res 65: 948-956, 2005.
13. Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW and Bryson P: Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol 14: 195-208, 2007.
14. Addis MF, Tanca A, Pagnozzi D, Rocca S and Uzzau S: 2-D PAGE and MS analysis of proteins from formalin-fixed, paraffin-embedded tissues. Proteomics 9: 4329-4339, 2009.
15. Tamarit J, Cabiscol E and Ros J: Identification of the major oxidatively damaged proteins in Escherichia coli cells exposed to oxidative stress. J Biol Chem 273: 3027-3032, 1998.
16. Matsunaga T, Kamiya T, Sumi D, Kumagai Y, Kalyanaraman B and Hara A: L-Xylulose reductase is involved in 9,10-phenanthrenequinone-induced apoptosis in human T lymphoma cells. Free Radic Biol Med 44: 1191-1202, 2008.
17. Risch HA: Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 90: 1774-1786, 1998.
18. Glorieux C, Dejeans N, Sid B, Beck R, Calderon PB and Verrax J: Catalase overexpression in mammary cancer cells leads to a less aggressive phenotype and an altered response to chemotherapy. Biochem Pharmacol 82: 1384-1390, 2011.
19. Lindgren PR, Cajander S, Backstrom T, Gustafsson JA, Makela S, and Olofsson JI: Estrogen and progesterone receptors in ovarian epithelial tumors. Mol Cell Endocrinol 221: 97-104, 2004.
20. Bardin A, Boulle N, Lazennec G, Vignon F and Pujol P: Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 11: 537-551, 2004.
21. Chan KK, Wei N, Liu SS, Xiao-Yun L, Cheung AN and Ngan HY: Estrogen receptor subtypes in ovarian cancer: a clinical correlation. Obstet Gynecol 111: 144-151, 2008.
22. De Stefano I, Zannoni GF, Prisco MG, Fagotti A, Tortorella L, Vizzielli G, Mencaglia L, Scambia G and Gallo D: Cytoplasmic expression of estrogen receptor beta (ERbeta) predicts poor clinical outcome in advanced serous ovarian cancer. Gynecol Oncol 122: 573-579, 2011.
23. Ciucci A, Gianferretti P, Piva R, Guyot T, Snape TJ, Roberts SM and Santoro MG: Induction of apoptosis in estrogen receptor-negative breast cancer cells by natural and synthetic cyclopentenones: role of the IkappaB kinase/nuclear factorkappaB pathway. Mol Pharmacol 70: 1812-1821, 2006.
24. Won YS, Lee SJ, Yeo SG and Park DC: Effects of female sex hormones on clusterin expression and paclitaxel resistance in endometrial cancer cell lines. Int J Med Sci 9: 86-92, 2012.
25. Tokuda E, Seino Y, Arakawa A, Saito M, Kasumi F, Hayashi SI and Yamaguchi Y: Estrogen receptor-alpha directly regulates sensitivity to paclitaxel in neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 2011.
26. Rousset S, Alves-Guerra MC, Ouadghiri-Bencherif S, Kozak LP, Miroux B, Richard D, Bouillaud F, Ricquier D and Cassard-Doulcier AM: Uncoupling protein 2, but not uncoupling protein 1, is expressed in the female mouse reproductive tract. J Biol Chem 278: 45843-45847, 2003.
27. Liu Y, Jiang H, He LY, Huang WJ, He XY and Xing FQ: Abnormal expression of uncoupling protein-2 correlates with CYP11A1 expression in polycystic ovary syndrome. Reprod Fertil Dev 23: 520-526, 2011.
28. Sastre-Serra J, Valle A, Company MM, Garau I, Oliver J and Roca P: Estrogen down-regulates uncoupling proteins and increases oxidative stress in breast cancer. Free Radic Biol Med 48: 506-512, 2010.